share_log

翰森製藥：2023年報

HANSOH PHARMA: ANNUAL REPORT 2023

Hong Kong Stock Exchange ·  Apr 29 09:43
Summary by Moomoo AI
HANSOH PHARMA（瀚森製藥）於2023年12月31日結束的財政年度，發布了全面的財務及運營表現報告。報告顯示，瀚森製藥在中國藥品市場的主要治療領域，包括腫瘤、感染、中樞神經系統疾病和代謝疾病方面，建立了領先地位。期內共有七款創新藥物獲批上市，並全部納入國家醫保目錄。報告期內新增六款產品獲批上市，其中一款創新藥物獲得兩個適應症的批准；另有十款創新藥物相關的二十三項新申請和臨床試驗獲批。創新藥物及合作產品的銷售收入約為人民幣686.5億元，占總收入的67.9%。公司在財務表現上保持行業領先，實現收入約人民幣1010.4億元，利潤約人民幣327.8億元。瀚森製藥的ESG評級於2023年被M...展開全部
HANSOH PHARMA（瀚森製藥）於2023年12月31日結束的財政年度，發布了全面的財務及運營表現報告。報告顯示，瀚森製藥在中國藥品市場的主要治療領域，包括腫瘤、感染、中樞神經系統疾病和代謝疾病方面，建立了領先地位。期內共有七款創新藥物獲批上市，並全部納入國家醫保目錄。報告期內新增六款產品獲批上市，其中一款創新藥物獲得兩個適應症的批准；另有十款創新藥物相關的二十三項新申請和臨床試驗獲批。創新藥物及合作產品的銷售收入約為人民幣686.5億元，占總收入的67.9%。公司在財務表現上保持行業領先，實現收入約人民幣1010.4億元，利潤約人民幣327.8億元。瀚森製藥的ESG評級於2023年被MSCI提升至AA級，並被標普全球評為「行業最佳進步企業」。董事會建議派發截至2023年12月31日止年度的末期股息每股14.22港仙。此外，公司已與審計委員會就計劃的審計範圍、時間、重大審計發現以及審計期間確定的任何重大內控缺陷進行了溝通，並向審計委員會提交了有關獨立性的道德要求遵守情況的聲明，並溝通了所有可能合理地被認為對獨立性有影響的關係和其他事項，並附有適當的保障措施。審計合夥人為安永的何兆豐。財務報表按照香港會計師公會發布的香港財務報告準則編制。
HANSOH PHARMA (HANSEN PHARMACEUTICALS) HAS ISSUED A COMPREHENSIVE FINANCIAL AND OPERATING PERFORMANCE REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023. HANSEN PHARMACEUTICALS HAS ESTABLISHED A LEADING POSITION IN THE MAJOR THERAPEUTIC AREAS OF THE CHINESE PHARMACEUTICAL MARKET, INCLUDING TUMORS, INFECTIONS, CENTRAL NERVOUS SYSTEM DISEASES AND METABOLIC DISEASES, THE REPORT SHOWS. A total of seven innovative drugs were approved for the market during the period, and all of them were included in the National Health Insurance Catalog. Six new products were approved for the market during the reporting period, with one innovative drug receiving approval for two indications; and 23 new applications and clinical trials for ten innovative drugs were approved. Sales revenue of innovative drugs and collaboration products amounted to approximately RMB686.5 billion...Show More
HANSOH PHARMA (HANSEN PHARMACEUTICALS) HAS ISSUED A COMPREHENSIVE FINANCIAL AND OPERATING PERFORMANCE REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023. HANSEN PHARMACEUTICALS HAS ESTABLISHED A LEADING POSITION IN THE MAJOR THERAPEUTIC AREAS OF THE CHINESE PHARMACEUTICAL MARKET, INCLUDING TUMORS, INFECTIONS, CENTRAL NERVOUS SYSTEM DISEASES AND METABOLIC DISEASES, THE REPORT SHOWS. A total of seven innovative drugs were approved for the market during the period, and all of them were included in the National Health Insurance Catalog. Six new products were approved for the market during the reporting period, with one innovative drug receiving approval for two indications; and 23 new applications and clinical trials for ten innovative drugs were approved. Sales revenue of innovative drugs and collaboration products amounted to approximately RMB686.5 billion, accounting for 67.9% of total revenue. The company remained the industry leader in financial performance with revenues of approximately RMB1010.4 billion and a profit of approximately RMB37.8 billion. Hanssen Pharmaceuticals' ESG rating was upgraded to AA in 2023 by MSCI and was named “Best Advancement Company in the Industry” by S&P Worldwide. The Board of Directors proposes to pay a final dividend of HK14.22 cents per share for the year ended 31 December 2023. IN ADDITION, THE COMPANY HAS COMMUNICATED WITH THE AUDIT COMMITTEE ON THE SCOPE OF THE AUDIT, TIMING, MAJOR AUDIT FINDINGS AND ANY SIGNIFICANT INTERNAL CONTROL DEFICIENCIES IDENTIFIED DURING THE AUDIT PERIOD, AND SUBMITTED TO THE AUDIT COMMITTEE A STATEMENT REGARDING COMPLIANCE WITH THE ETHICAL REQUIREMENTS OF INDEPENDENCE, AND COMMUNICATED ALL REASONABLY DEEMED REASONABLE Relationships and other matters that have an impact on independence, with appropriate safeguards in place. The audit partner is Ho Siu-feng at EY. Financial statements are prepared in accordance with the Hong Kong Financial Reporting Guidelines published by the Hong Kong Association of Accountants.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more